Sunday 18 October 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 343.5% and free cash flow fell 74.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.57
1.02
−8.80%
Follow TTRX
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
0.87 | 1.55 |
Net Debt/EBITDA |
0.96 | 0.50 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.80 | 0.77 |
Capex/Depreciation |
(0.28) | (2.09) |
| (141.67%) | 0.00% | |
| (44.95%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
395.80% | (453.44%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.08 | 0.40 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.10) | (0.05) |
Cash per Share |
0.18 | 0.03 |
Shareholders Equity per Share |
0.17 | (0.01) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.17 | (0.01) |
Free Cash Flow |
(2.72) | (1.46) |
Working Capital |
(0.81) | 0.39 |
Capital Expenditures |
(0.15) | (0.10) |
Net Current Asset Value |
(2.28) | (1.13) |
| Other line items | ||
Quick Ratio |
0.85 | 1.23 |
Depreciation/Fixed assets |
0.00 | 0.00 |
Cash ROIC |
(27.82%) | (210.13%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.09) | (0.05) |
Capex per Share |
(0.01) | 0.00 |
Average Payables |
1.80 | — |
Average Assets |
7.11 | — |
Average Common Equity |
2.25 | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates